ClinicalTrials.gg
CompletedNCT05381142Updated Jul 27, 2022

A Study to Learn More About How the Study Treatment Elinzanetant (or BAY3427080) Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body After Taking Single and Multiple Doses in Healthy Women Aged 40 to 65 Years

A Phase 1 interventional study of Elinzanetant (BAY3427080) and Placebo in Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes and Healthy Volunteers, sponsored by Bayer. Completed at 1 site in China. Open to female participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-27.

Sponsored by Bayer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing elinzanetant in Hot Flashes — none open to participants now, 1 under way, 1 of them phase 3. elinzanetant · Hot Flashes.

Enrollment
12th of 13
16 · median 64
Started
2022
with 4 others
Phase 1
7 of 13
none open now
Registered
9th of 13
by date
Lead sponsor
13 of 13
Bayer

Among the 13 studies testing elinzanetant in Hot Flashes, this one is the 12th largest by enrollment, is one of 5 that started in 2022, is one of 7 in phase 1, and was the 9th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

None of the 13 studies testing elinzanetant in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →

About elinzanetant

elinzanetant: first FDA approval 2025 (LYNKUET), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 65 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing elinzanetant in Hot Flashes as a file.
02

Study summary

Researchers are looking for a better way to treat men and women with vasomotor symptoms, a condition of having hot flashes caused by hormonal changes.

In women, these hormonal changes happen in the time around their menopause, the last period (menstrual cycle) a woman has. After the menopause, the ovaries produce less and less sex hormones as a result of the natural ageing process and related hormonal adaptations. The decrease in hormones produced can lead to various symptoms that may be troublesome. Vasomotor symptoms are also seen in men.

The study treatment, elinzanetant, is under development to treat symptoms caused by hormonal changes. It works by blocking a substance called neurokinin, which is thought to play a role in starting hot flashes.

Previous studies have been done. This study will provide information on how to use elinzanetant in Chinese people.

The main purpose of this study is to learn how much of the study treatment elinzanetant gets into the participants' blood when a single dose is taken in healthy Chinese women.

To answer this question, the researchers will measure:

  • The (average) total level of elinzanetant in the blood (also called AUC)
  • The (average) highest level of elinzanetant in the blood (also called Cmax) The researchers also want to learn how much elinzanetant gets into the blood when taken for 6 days in a row.

Dependent on the treatment group, the participants will either take elinzanetant or placebo. First, a single dose of two capsules is taken by mouth and later multiple doses once a day for another 6 days in a row are taken.

Each participant will be in the study for approximately 22 days including 7 treatment days in total. Participants will stay in-house for 16 days. In addition, one visit to the study site prior start and four visits after the in-house period are planned.

During the study, the study team will:

  • Do physical examinations
  • Take blood and urine samples
  • Check vital signs
  • Examine the participants' heart health using electrocardiogram (ECG)
  • Ask the participants questions about how they are feeling and what adverse events they are having.

An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.

03

Conditions studied

  • Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
  • Hot Flashes
  • Healthy Volunteers

Browse trials for

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 40 to 65 years of age inclusive, at the time of signing the .
  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs, laboratory tests and (ECG).
  • Race: Chinese in China mainland.
  • Body weight of at least 40 kg and (BMI) within the range 18.0 and 30.0 kg/m\^2 (inclusive) at screening.
  • Female:

    • Women of will have to use highly effective non-hormonal when having sexual intercourse with a male partner from signing the informed consent form until 5 days after last dose of the study intervention.
    • Women of non-childbearing potential are not required to use contraception.
  • Capable of giving signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • Any abnormal findings in medical history and physical examination at screening or Day -1 which in the opinion of the investigators, may put the participant at risk because of her participation in the trial or provide difficulties in interpreting the trial data.
  • History or evidence of any clinically relevant cardiovascular, gastrointestinal, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other clinically relevant disease, as judged by the investigator.
  • Known to the study interventions (active substances, or of the preparations).
  • Use of any systemic or topical medicine or substance which oppose the study objectives, or which might influence them within 4 weeks before first administration of study intervention. This includes but is not limited to CYP P450 inducers/inhibitors, OATP substrates or P-gp substrates with narrow therapeutic range (e.g. digoxin, dabigatran etc).
  • Regular use of therapeutic drugs or supplements, e.g., carnitine products, anabolics, high dose vitamins.
  • Use of herbal drugs or natural remedies, e.g. St. John's wort within 4 weeks before first study intervention administration.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Elinzanetant (BAY3427080)

    Healthy female participants who meet all of the inclusion criteria and do not meet any of the exclusion criteria will be randomized to treatment with elinzanetant.

    Drug: Elinzanetant (BAY3427080)

  • Placebo comparator
    Placebo

    Healthy female participants who meet all of the inclusion criteria and do not meet any of the exclusion criteria will be randomized and assigned to treatment with placebo.

    Drug: Placebo

Interventions

  • Elinzanetant will be administered as a single dose on Study Day 1 and a multiple dose once daily for another 6 consecutive days on Study Day 8 to Study Day 13.

    Also known as: NT-814

  • DrugPlacebo

    Matching placebo will be administered the same as Elinzanetant (BAY3427080)

06

What researchers measure

Primary outcomes

  1. Cmax: maximum observed drug concentration in measured matrix after single dose administration

    Time frame: From pre-dose up to 168 hours after first dosing

  2. AUC: area under the concentration vs. time curve from zero to infinity after single dose

    AUC(0-tlast) will be used as the main parameter if AUC cannot be reliably determined

    Time frame: From pre-dose up to 168 hours after first dosing

  3. Cmax,md: maximum observed drug concentration in measured matrix after multiple dose administration

    Time frame: From pre-dose up to 180 hours after last dosing

  4. AUC(0-24)md: AUC from time 0 to 24 hours for multiple dosing

    Time frame: From pre-dose up to 180 hours after last dosing

Secondary outcomes

  1. Number of participants with and severity of treatment-emergent adverse events (TEAEs)

    Time frame: From first dose of study intervention until follow-up visit on day 21

07

Study locations

1 site
  • The First Affiliated Hospital of Guangzhou University of TCM
    Guangzhou, Guangdong 510405, China
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jul 2022, 1 month.

Of 10 phase 1 interventional studies under Hot Flashes, half reached primary completion within 3 months of starting (the median); a quarter within 1 and three quarters within 9. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2022
First posted
May 19, 2022
StartActual
May 23, 2022
Primary completionActual
Jul 11, 2022
CompletionActual
Jul 11, 2022
Last update
Jul 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05381142
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
May 19, 2022
Start date
May 23, 2022
Primary completion
Jul 11, 2022
Completion
Jul 11, 2022
Last update
Jul 27, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elinzanetant

Start the discussion